Sinus Lift / Sinus Floor Augmentation Template

Sinus lift/sinus augmentation.

RMH: Medical history reviewed/updates
Vitals: BP/pulse; other vitals if indicated

Site: Site/tooth area
Implant site: #Tooth number(s)
Pre-op bone height: Pre-op bone height

Consent: Consent/PARQ reviewed; signed/verbally obtained

Anesthesia: Anesthetic used
Carps: Carpules/amount

Graft/defect support: Reason grafting required; defect/recession dimensions; site/tooth
Image support: Radiograph/CBCT/intraoral photo of defect
Material details: Graft/biologic/membrane/suture material and amount
Prognosis/follow-up: Healing expectations and follow-up plan

Procedure:
Lateral window approach.
Crestal approach.
Incision made.
Flap elevated.
Osteotomy performed.
Schneiderian membrane elevated.
Membrane integrity confirmed.
No perforation.
Graft material: Graft material
Graft placed.
Membrane placed over window.
Flap repositioned.
Sutured with: Suture material/size
Hemostasis achieved.

Complications: None or describe.

Patient tolerance: Tolerance/response.

Post-op instructions: Instructions reviewed.
No nose blowing.
Sneeze with mouth open.
No smoking.
No straws.
Rx: Prescription or none

Healing period before implant: Healing period before implant

NV: Next visit

Documentation requirements

Sinus floor augmentation is one of the highest-fee adjunctive procedures in implant dentistry, and the most heavily reviewed because of the anatomic risk (Schneiderian membrane perforation, infection seeded into the sinus, graft displacement into the antrum, oroantral fistula). The chart needs to prove (1) the patient was a documented candidate (CBCT-confirmed sub-antral atrophy, sinus health screened, medical history clear of contraindications), (2) informed consent specifically addressed sinus-related risks, (3) the procedure was performed under guideline-concordant conditions (membrane integrity confirmed, perforation managed if it occurred, graft material with lot traceability), and (4) the staged healing and implant plan are explicit. A defensible note must contain:

• Side and site — right maxillary sinus vs left maxillary sinus, planned implant tooth number(s) (e.g., "#14 site, left maxilla" or "#3 site, right maxilla"). D7951 / D7952 are per-sinus; bilateral procedures = D7952 x 2 or D7951 x 2.
• Approach — explicit "lateral window approach" (D7952) vs "vertical / crestal / osteotome / Summers approach" (D7951). The descriptor language is what triggers the correct CDT code; the chart should mirror the descriptor.
• Pre-op CBCT measurements — sub-antral bone height in mm at the planned implant site (e.g., "residual sub-antral bone height 3.2 mm at #14 site"), sinus floor anatomy (presence and location of septa, lateral wall thickness, antroposterior dimension of the sinus), Schneiderian membrane assessment (thickness in mm; thickening >2 mm or pseudocysts noted; bilateral comparison), patency of ostiomeatal complex, and any pathology (mucosal cyst, retention cyst, odontogenic source, opacification suggestive of sinusitis). CBCT (D0364-D0368) is effectively standard-of-care imaging for sinus augmentation per AAOMS / AAID position papers.
• Sinus health screen — no active rhinosinusitis (no purulent drainage, no facial pressure / pain on tap, no recent URI in last 4-6 weeks), no untreated odontogenic source (apical pathology on adjacent #14, #15, #16 — all should be ruled out or treated before lift), patency confirmed by history / imaging. Active sinus infection is a placement-deferring finding; document the deferral and re-evaluation plan if applicable.
• Medical history reviewed and updated today — meds, conditions, allergies. Highest-yield items for sinus augmentation: anticoagulants / antiplatelets (warfarin, apixaban, rivaroxaban, dabigatran, clopidogrel — INR if on warfarin), antiresorptives / antiangiogenics (oral and IV bisphosphonates, denosumab, romosozumab — duration of therapy and MRONJ risk; sinus lift is a major maxillary surgical procedure with documented MRONJ risk), uncontrolled diabetes (recent HbA1c; predictable regeneration above ~A1C 8.0 is reduced), active smoking (single strongest modifiable risk factor for sinus graft failure and membrane perforation healing complications — quantify pack-years and document cessation counseling), immunosuppression / chemotherapy / head and neck radiation history (prior radiation dose / field; HBO consideration), chronic rhinosinusitis or seasonal allergies / atopy (relative consideration; coordinate with ENT if active), history of sinus surgery (FESS, Caldwell-Luc), and psychiatric / neurologic conditions affecting post-op compliance with sinus precautions.
• Vitals (BP, pulse) at minimum — required by most state boards on a major surgical visit. Hypertensive urgency is a placement-deferring finding.
• Informed consent / PARQ specific to sinus augmentation — risks beyond standard surgical risk: Schneiderian membrane perforation (the single most common intraoperative event, reported at ~10-30% for lateral window in published series; managed intraoperatively when small), graft displacement into the sinus, sinusitis (acute or chronic), oroantral fistula formation, partial or complete graft loss, infection requiring drainage, persistent facial swelling or bruising, anesthesia-related risks, possibility regenerative goal not achieved and additional grafting / staged augmentation / abandonment of the implant plan may be needed, alternatives (no treatment with prosthetic plan revised away from posterior maxillary implants, short implants 5-7 mm without lift if residual height allows, zygomatic or pterygoid implants, removable prosthesis instead of implant-supported). Note signed vs verbal; many practices require written consent specifically for sinus augmentation given the morbidity profile.
• Anesthesia — agent, concentration, vasoconstrictor, technique (PSA block + greater palatine + infiltration is typical for D7952 lateral window; infiltration alone often adequate for D7951 osteotome). Carpule count. Sedation level if used (nitrous, oral, IV) and the corresponding sedation code (D9230 / D9239 / D9243) billed separately.
• Surgical access (lateral window approach, D7952) — incision design (crestal with vertical releases vs trapezoidal flap); flap reflection (full-thickness mucoperiosteal); identification of the lateral wall of the maxillary sinus; osteotomy window dimensions and location (e.g., "10 x 6 mm window centered ~3 mm above sinus floor on lateral wall over #14"); osteotomy method (rotary round bur, piezoelectric, trephine — piezoelectric reduces membrane perforation rate per published systematic reviews); window handling (hinged inward and elevated with the membrane vs removed and replaced as a bone cap).
• Surgical access (crestal / osteotome approach, D7951) — crestal incision over the planned implant site; flap reflection; pilot osteotomy prepared to ~1-2 mm short of the sinus floor; sinus floor cortex gently fractured with Summers osteotomes (graduated diameters) or hydraulic sinus elevation system (Crestal Approach Sinus Kit, Densah burs, hydraulic balloon); membrane elevated by graft material pushed through the osteotomy or by hydraulic pressure.
• Schneiderian membrane elevation — explicit "membrane elevated" language; method (sinus curettes graduated, blunt dissectors, hydraulic); area of elevation (anterior, posterior, medial); height of elevation in mm at the apical-most point.
• Membrane integrity confirmed — the single most important documentation element. Explicit "membrane integrity confirmed; no perforation noted on Valsalva maneuver" OR description of perforation if it occurred (location, size — small <5 mm, medium 5-10 mm, large >10 mm — and management: collagen membrane patch / suture / abandonment of grafting). Membrane perforation rate is ~10-30% for lateral window per published series; the chart that documents recognition and management is defensible. Silence on membrane integrity is a documentation deficiency.
• Graft material — product, manufacturer, type, lot number, and amount — required by FDA tissue-tracking regulations (21 CFR 1271) for human-derived materials (allograft) and best-practice for xenograft and alloplast. Examples: "Bio-Oss xenograft (Geistlich), particle size 0.25-1 mm, 2.0 g, lot 26B0481" or "MinerOss FDBA + Bio-Oss xenograft 50:50 composite, 1.5 cc total, lots 26A0922 / 26B0481." Most carrier narratives expect a unit measurement (cc or g or mL).
• Biologic adjunct — if used, name and lot (rhPDGF-BB / GEM 21S, recombinant BMP-2 / Infuse, Emdogain, PRF / L-PRF / A-PRF prepared chairside). PRF is increasingly common in sinus protocols. BMP-2 has FDA on-label use in sinus augmentation; document the indication and lot.
• Membrane (lateral window cover, D7952) — resorbable collagen membrane (Bio-Gide, BioMend, OsseoGuard) placed over the lateral osteotomy window to contain graft is standard; product and lot. The membrane is generally bundled into D7952 per descriptor and most carrier policies — same logic as the D7953 membrane bundling rule. Document but do not separately bill D4266 / D4267 at a D7952 site.
• Closure — primary closure achieved with tension-free flap (often requires periosteal release for D7952 to advance the flap over the augmented site); suture material, size, pattern (e.g., "4-0 PTFE / Vicryl, simple interrupted x 6 + horizontal mattress x 2"); knot count when relevant.
• Hemostasis — achieved; method if notable (pressure, hemostatic agent, gelfoam, surgicel, electrocautery).
• Concurrent implant placement (when applicable for D7951) — when D7951 is performed simultaneously with implant placement (the typical osteotome simultaneous protocol), document the implant brand / system / size / lot, insertion torque, and primary stability. Bill D7951 + D6010 same-DOS with documentation distinguishing the two procedures. For D7952 lateral window, simultaneous implant placement is possible only when residual ridge height (typically >4-5 mm) is adequate for primary stability; otherwise staged.
• Complications — explicit "None" or describe (membrane perforation with size and management, graft displacement, intraoperative bleeding from the posterior superior alveolar artery in the lateral wall, dehiscence of the bone window, encounter with septum, inadvertent communication with the nasal cavity through the medial sinus wall).
• Patient tolerance / response — tolerated well, vitals stable, no adverse events.
• Post-op instructions specific to sinus precautions — no nose blowing (single most important sinus instruction; positive pressure can dislodge graft and rupture the elevated membrane), sneeze with mouth open (release pressure through the mouth, not the nose), no smoking (markedly higher graft failure and infection rates; sinus surgery in active smokers is high-risk), no straws (negative pressure), no scuba diving / flying / pressure changes for 2-4 weeks, no heavy lifting or straining for 1-2 weeks, soft diet 1 week, no chewing on the surgical side, gentle saline rinses (not nasal sprays for 1-2 weeks), saline nasal saline irrigation per ENT-style protocol when indicated, return precautions (uncontrolled bleeding, increasing pain after 72 h, fever, purulent drainage from nose or socket, persistent nasal congestion or facial pressure, exposed graft material).
• Prescriptions — antibiotic regimen (sinus augmentation universally warrants prophylactic antibiotics per AAOMS / AAID guidance — commonly amoxicillin / clavulanate 875/125 mg BID x 7-10 days, or clindamycin 300 mg QID for penicillin-allergic patients; some protocols add metronidazole), decongestant (pseudoephedrine 30-60 mg q6h prn for 5-7 days, or oxymetazoline nasal spray short-course; coordinates with sinus drainage), analgesic regimen (ibuprofen 600 mg q6h prn ± acetaminophen 500 mg alternating per AAOMS / ADA NSAID-first guidance), chlorhexidine 0.12% rinse BID for 1-2 weeks, steroid burst when significant edema is anticipated (medrol dose pack or dexamethasone — practice-dependent).
• Healing period before implant placement — explicit timeline. Lateral window staged (D7952 alone today): typically 6-9 months before implant osteotomy. Crestal / osteotome simultaneous (D7951 + D6010 same-DOS): standard implant osseointegration of 4-6 months from today. Crestal / osteotome staged (D7951 alone today): typically 3-6 months before implant. The prosthetic endpoint is what justifies the procedure; document the planned re-evaluation imaging (CBCT) and the implant timeline.
• Provider signature and assistant initials.

Two phrases that defuse the most common audit questions on sinus codes: an explicit pre-op CBCT measurement ("residual sub-antral bone height 3.2 mm at #14 site"), and explicit membrane integrity language ("Schneiderian membrane elevated under direct vision; integrity confirmed on Valsalva; no perforation"). Both track AAOMS / AAID descriptor expectations directly.

Common denial reasons

Sinus augmentation carries the highest dollar exposure in adjunctive implant surgery and is one of the most reviewed CDT code pairs in implant dentistry. The most frequent reasons D7951 / D7952 are denied, downgraded, or recouped:

• No pre-op CBCT documented — D7951 / D7952 effectively require pre-op CBCT (D0364-D0368) showing the residual sub-antral bone height in mm, sinus floor anatomy, and Schneiderian membrane status. Pano + PA alone is rarely defensible for a sinus lift; carriers commonly request CBCT on review by Delta Dental, BCBS, Aetna, and FEDVIP carriers.
• No prosthetic plan documented — chart says "sinus lift performed" without naming the planned implant tooth/site. The single most common denial reason on D7951 / D7952 review. "Planned implant #14 in 6-9 months pending healing" is the defensible language.
• Schneiderian membrane integrity not documented — silence on membrane integrity is a documentation deficiency. Explicit "membrane elevated under direct vision; integrity confirmed; no perforation noted on Valsalva maneuver" is the defensible language. When perforation occurs, document size and management (collagen membrane patch / suture / abandonment).
• Graft material lot number not recorded — FDA tissue-tracking regulations (21 CFR 1271) and most carrier clinical policies require the product, manufacturer, and lot number for human-derived allograft. Missing lot number is cited as a documentation deficiency on audit.
• D7952 + D4266 / D4267 same site billed separately — the membrane covering the lateral osteotomy window is bundled into D7952 per descriptor and most carrier policies. Auto-rejected on most carrier edits and is a common upcoding pattern caught by major carriers.
• D7951 billed when the case did not actually elevate the sinus floor — when the osteotomy is short of the sinus floor and no membrane elevation occurred, D7951 is not the correct code; the placement is just D6010 alone. Carriers occasionally audit this when the CBCT measurements don't support membrane elevation.
• D7951 + D6010 bundled by carrier into D6010 alone — some carriers process simultaneous osteotome lifts as bundled into the implant placement. The narrative defense is that the sinus elevation was a discrete procedure beyond the routine implant osteotomy, with documented graft material and elevation in mm.
• D7952 billed simultaneously with D6010 in a clearly inadequate residual ridge — simultaneous implant placement with lateral window requires adequate residual ridge height (typically >4-5 mm) for primary stability. When the residual ridge is <4 mm and an implant is reported same-DOS, carriers may flag the implant as not achievable and deny one or both codes.
• D7952 billed bilaterally in a clearly inappropriate single session — some carriers prefer staged bilateral procedures and may deny one of the bilateral lifts citing morbidity / post-op management concerns.
• Active sinus pathology not addressed pre-op — when the pre-op CBCT shows opacification, mucosal cyst, or other pathology and the chart is silent on sinus health screening or ENT clearance, the augmentation can be denied retroactively or the patient can have a complication-related claim issue.
• Smoker / uncontrolled diabetic without risk-factor narrative — clinical-policy bulletins flag these patients as higher-risk for sinus graft failure and may require an explicit narrative addressing risk before paying.
• Coverage exclusion — many plans list sinus augmentation as a non-covered cosmetic / elective service tied to elective implant placement. Verify before treatment; if non-covered, the patient pays out-of-pocket per the financial agreement.
• "Not medically necessary" denial — when the prosthetic plan is weak (e.g., posterior maxillary edentulism with adequate function on a removable partial denture and no specific implant plan), the augmentation is denied as not necessary to the medical or dental health of the patient.
• Default-template chart notes — identical sinus measurements, graft volumes, membrane products across multiple patients flagged as templating. Medicaid MCO and several commercial carriers run template-fingerprint review on high-fee surgical codes.
• Failure to schedule or document re-evaluation imaging — the prosthetic goal is the indication for the procedure; not following through with re-imaging at 6-9 months weakens the chart's defense if the case is later audited.
• Wrong code selected — D7951 billed for a true lateral window case (or vice versa). The descriptor language must match the surgical approach. Documenting "lateral window osteotomy on the lateral wall" but billing D7951 (vertical / crestal approach) is auto-rejected on review. The chart should mirror the descriptor.

Related templates